Epicardial propranolol administration for ventricular arrhythmias in dogs: matrix formulation and characterization
dc.contributor.author | Siden, Rivka | en_US |
dc.contributor.author | Flowers, William E. | en_US |
dc.contributor.author | Levy, Robert J. | en_US |
dc.date.accessioned | 2006-04-10T15:26:30Z | |
dc.date.available | 2006-04-10T15:26:30Z | |
dc.date.issued | 1992 | en_US |
dc.identifier.citation | Siden, Rivka, Flowers, William E., Levy, Robert J. (1992)."Epicardial propranolol administration for ventricular arrhythmias in dogs: matrix formulation and characterization." Biomaterials 13(11): 764-770. <http://hdl.handle.net/2027.42/30361> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6TWB-48HRKFS-P5/2/9670497f2d43de462e27e3a59f30bd07 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/30361 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1391398&dopt=citation | en_US |
dc.description.abstract | The effect of propranolol on the prevention of ventricular tachycardia/fibrillation (VT/VF) due to acute coronary ischaemia was studied in dogs. A series of propranolol-polymer controlled release matrices in slab configuration using various polyurethanes and a polyurethane-silicone rubber copolymer were formulated and characterized. In general, drug release in vitro occurred with an initial burst phase followed by an exponentially declining delivery rate; the silicone rubber containing copolymer preparation had more sustained release properties than did pure Polyurethane matrices. In the animal studies, dogs underwent 5-hourly 10 min complete occlusions of the left anterior descending coronary artery (LAD), followed by 50 min normal perfusion. During non-drug occlusions VT occurred at a frequency of 1.22 +/- 0.12 episodes/min. A propranolol-polyurethane matrix (30% w/w, 28-42 mg) was placed on the ischaemic zone of the left ventricular epicardium immediately after the fifth occlusion. After an hour of drug delivery a sixth occlusion took place. The number of arrhythmia episodes both before and after drug were quantified and compared. The time to ventricular fibrillation (when present) and the mean blood pressure were also assessed. The drug patch delivered propranolol at a dose of 140 +/- 45 [mu]g/kg by the conclusion of the 1 h study period. Therapeutic drug levels were achieved in the peripheral blood samples (8.7-43.7 ng/ml) and were enhanced in coronary venous samples (360.9-556.2 ng/ml). Reduction of blood pressure and proarrhythmic events following epicardial controlled release propranolol administration were noted but were not statistically significant. Arrhythmia episodes before and after propranolol were not found to be significantly different (VT/min 1.02 +/- 0.31 and 1.22 +/- 0.12). The occlusion time until VF occurred was also not significantly different before versus after propranolol (t = 5.38 +/- 0.86 and 5.28 +/- 0.48 min). Therefore, despite attaining clinically therapeutic plasma levels, epicardial administration of propranolol was not found to be effective for the prevention of VT/VF due to acute ischaemia. | en_US |
dc.format.extent | 937111 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Epicardial propranolol administration for ventricular arrhythmias in dogs: matrix formulation and characterization | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Materials Science and Engineering | en_US |
dc.subject.hlbsecondlevel | Dentistry | en_US |
dc.subject.hlbsecondlevel | Biomedical Engineering | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan Medical School and Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan Medical School and Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan Medical School and Department of Pharmaceutics, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.identifier.pmid | 1391398 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/30361/1/0000763.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0142-9612(92)90015-G | en_US |
dc.identifier.source | Biomaterials | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.